Small cell lung cancer (SCLC) accounts for approximately 13% of all lung cancer cases. Small cell lung cancer is characterized by frequent relapse, and current treatments lack tumor specificity. Arginine is a non-essential amino acid for human normal cells but critical to some tumor cells that cannot synthesize arginine. Therefore, arginine deprivation has become a potential therapeutic option for selected tumors.
Asparagine deprivation is therefore selectively cytotoxic to ALL cells, while sparing normal cells.
Similarly, arginine is another amino acid that is non-essential to normal cells but crucial to some tumor cells. It plays an important role in cellular functions such as protein synthesis, nitric oxide production, and polyamine production. 8 Biologically, arginine can be metabolized by three enzymes: arginase, ADI, and arginine decarboxylase. There are primarily two ways to induce arginine depletion.
One is ADI, an enzyme obtained from mycoplasma that catabolizes arginine to citrulline and ammonia and has been reported to have a powerful antitumor effect in ASS1-deficient cancers including HCC, prostate cancer, melanoma, and leukemia. [9] [10] [11] [12] Another is rhArg, an enzyme that can degrade arginine to ornithine and urea and has shown anticancer activity in certain tumors. 13, 14 Both of these agents are modified by PEG, which can reduce their immunogenicity and enhance bioavailability. 15, 16 The main difference between ADI and rhArg is that the former has little antitumor effect against tumors expressing ASS1, whereas rhArg can be effective against these tumors. Ornithine transcarbamylase is another crucial enzyme in the urea cycle and catalyzes ornithine to citrulline, and it might explain resistance to rhArg. 17 BCT-100, one type of pegylated rhArg, has shown a significant anticancer effect against several tumors and has completed formal phase I/II clinical trials in the treatment of HCC patients with encouraging results. 18 Few studies have highlighted the role of BCT-100 in SCLC. We explored the mechanism of arginine depletion with BCT-100 in SCLC as a promising therapeutic approach.
| MATERIALS AND METHODS

| Cell lines and culture
A panel of 9 SCLC cell lines (NCI-H69, DMS79, NCI-H187, NCI-H209, NCI-H446, NCI-H510A, NCI-H526, NCI-H841, and SW1271) and 1 NSCLC cell line (A549) were purchased from ATCC (Manassas, VA, USA). All cell lines were maintained on RPMI-1640 medium (Gibco, Life Technologies, Carlsbad, CA, USA) supplemented with 10% FBS (Gibco) in a humidified atmosphere of 5% CO 2 at 37°C.
| Pegylated recombinant human arginase (BCT-100)
BCT-100 was kindly provided by Bio-Cancer Treatment International
Limited, Hong Kong. 
| Western blot analysis
| Cell viability assay
Small cell lung cancer cells were seeded in a 96-well plate, approximately 10 4 /well. After drug exposure, 10 μL MTT (0.5 mg/mL) (Sigma-Aldrich) was added to each well for 3 hours, followed by triple lysis solution (10% SDS, 5% isobutanol, and 0.012 mol/L HCl in water), 100 μL/well for 2 hours. Optical density was measured at 570 nm using a microplate reader FluoStar Optima (BmgLabtec, Ortenberg, Germany).
| Arginine concentration detection
The arginine level in cells, serum, and tumor was measured using an L-arginine ELISA kit purchased from Immundiagnostik (Bensheim, Hessen, Germany). The procedure was carried out according to the manufacturer's instructions. In brief, derivatized samples and standards were incubated with L-arginine antibody overnight at 4°C, followed by incubation with peroxidase conjugate for 1 hour at room temperature, tetramethylbenzidine substrate for 10 minutes in the dark. Wash buffer was needed between every step and stop solution added to halt the reaction. Absorbance (450 nm), using a reference (620 nm), was measured using a microplate reader FluoStar Optima. 
| Cell apoptosis assay
The TUNEL assay was undertaken using a Click-iT Plus TUNEL Assay kit (Life Technologies) according to the standard protocol provided by the manufacturer. Tissue deparaffinization, fixation, and permeabilization were required before the TUNEL assay. Tumor sections were immersed in TdT reaction buffer, then changed to new TdT reaction buffer that contained EdUTP, TdT, and TdT enzyme. Samples were incubated with TUNEL reaction cocktails followed by DAPI (Life Technologies) staining. Images were captured using a Nikon Ni-U fluorescence microscope (Nikon, Tokyo, Japan).
| Immunofluorescence staining
Deparaffinized, fixed, and permeabilized tumor sections were blocked with 3% BSA for 1 hour at room temperature, followed by incubation with PEG (RevMAb) and cytokeratin 1 (Santa Cruz 
| Statistical analysis
All data were obtained from at least three independent experiments and are shown as mean ± SD. Statistical analysis of data was carried out using Student's two-tailed t test by Prism (GraphPad Software, La Jolla, CA, USA).
| RESULTS
| Sensitivity of SCLC to BCT-100 correlated with expression of ASS1 and OTC
Argininosuccinate synthetase and OTC are two essential enzymes for arginine synthesis in the urea cycle. We tested the basal expression of ASS1 and OTC protein expression levels in a panel of 9 SCLC cell lines (H69, DMS79, H187, H209, H446, H510A, H526, H841, and SW1271) using western blot analysis ( Figure 1A ). Expression of ASS1 was relatively high in H69, DMS79, and H510A cells, whereas OTC showed high expression in H841 and SW1271 cells.
In addition, NSCLC A549 cells were included in this study as an example with intact urea cycle, due to high expression of both ASS1
and OTC as previously reported ( Figure 1A ). 20 To evaluate the cell viability of BCT-100 in these SCLC and NSCLC cell lines, all cell lines were exposed to increasing concentrations of BCT-100 for 3 days. 
| Apoptosis induced by BCT-100 was accompanied by arginine decrease in SCLC
As BCT-100 is a pegylated recombinant human arginase, PEG was used to indicate the accumulation and location of BCT-100 in vitro and in vivo. Intracellular BCT-100 was present following BCT-100 treatment in H446, H510A, and H526 cells in a dose-dependent manner ( Figure 2A ). Intracellular arginine concentration was significantly decreased in a dose-dependent fashion ( Figure 2B ). At the same time,
we observed apoptosis following BCT-100 treatment as evidenced by upregulation of cleaved PARP ( Figure 2C ) and an increase in apoptotic cells as evidenced on annexin V/7-AAD staining ( Figure 2D ). Figure 3A ) and O 2 − ( Figure 3B ) production in the BCT-100 treatment arms. The GSH level, stained by CMFDA, was decreased in a dose-dependent manner following BCT-100 treatment ( Figure 3C ).
| Effect of BCT-100 on ROS production and GSH content
Moreover, SOD-1 and TRXR were also decreased in a dose-dependent fashion following BCT-100 exposure ( Figure 3D ).
| Mitochondrial membrane depolarization and mitochondria-dependent apoptosis triggered by BCT-100 treatment
JC-1 staining revealed that H446, H510A, and H526 cells were experiencing mitochondrial membrane depolarization following BCT-100 exposure for 3 days ( Figure 3E ). Smac and cytochrome C are mitochondrial biomarkers that play a crucial role during apoptosis.
Both Smac and cytochrome C were released from mitochondrion to cytosol in a dose-dependent fashion ( Figure 3F ). In addition, a ROS scavenger, N-acetylcysteine, could reverse the apoptosis triggered by BCT-100, and GSH inhibitor, buthionine sulfoximine, could potentiate the cytotoxic effect of BCT-100 treatment ( Figure S2 ).
| Cell cycle arrest in SCLC after exposure to
BCT-100
Cyclin A2, cyclin B1, cyclin E1, cyclin E2, CDK2, and CDK4 were downregulated in a time-dependent manner. This indicated that G 1 cell cycle arrest was induced by BCT-100 ( Figure 4A ). Flow cytometry indicated that BCT-100 induced G 1 cell cycle arrest in SCLC cells ( Figure 4B ). Figure 5D ).
Intratumoral arginine concentrations in these two xenograft models were also decreased in a dose-dependent manner. The concentration in the control, 20 mg/kg, and 60 mg/kg groups in the H446 xenograft was 11.7 ± 1.3, 7.8 ± 0.5, 0.48 ± 0.07 μmol/L, respectively. In the H510A xenograft, the corresponding arginine level was 10.01 ± 0.9, 3.89 ± 0.5, and 1.26 ± 0.3 μmol/L, respectively ( Figure 5E ).
| Apoptosis and G 1 cell cycle arrest induced by BCT-100 in vivo
Cleaved PARP was evident in the 60 mg/kg BCT-100 treatment arm in H446 and H510A xenografts ( Figure 6A ). We used TUNEL staining to indicate the DNA strand breaks after BCT-100 treatment. The TUNEL-positive signals were much higher in the 60 mg/kg group than the control group in both H446 and H510A xenografts ( Figure 6B ). Cyclin A2, cyclin B1, and CDK4 were decreased in a dose-dependent fashion in both xenografts ( Figure 6A ). These results were consistent with in vitro data that indicated G 1 cell cycle arrest following BCT-100 exposure.
| Localization of BCT-100 in H446 and H510A xenografts
As BCT-100 is conjugated with PEG, its ability to pass through the nuclear membrane is uncertain. We used DAPI, cytokeratin 1, and PEG to indicate the nucleus, cytoplasm, and BCT-100, respectively.
We observed that PEG overlapped with cytokeratin 1 and very little PEG localized to the nucleus, indicating that BCT-100 was mainly located in the cytoplasm ( Figure 6C ).
| DISCUSSION
BCT-100 showed an inhibitory effect on tumor growth in SCLC and triggered apoptosis through oxidative stress as well as G 1 cell cycle arrest in vitro. In H446 and 510A xenograft models, BCT-100
(60 mg/kg) suppressed tumor growth and prolonged median survival.
The intracellular and intratumoral arginine concentrations were sharply decreased in BCT-100 treatment groups, resulting in cellular apoptosis and G 1 cell cycle arrest.
F I G U R E 2 BCT-100 decreased intracellular arginine concentration and induced apoptosis of H446, H510A, and H526 cells. A,B, Intracellular PEG was accumulated (A) and intracellular arginine concentration (B) was decreased following BCT-100 treatment for 72 hours. C, Cleaved PARP (C-PARP) was upregulated after BCT-100 treatment for 72 hours. D, Apoptotic cells were increased by BCT-100 treatment, evidenced by annexin V and 7-AAD staining and flow cytometry analysis. Data are represented as mean ± SD of three independent experiments. *P < .05, **P < .01, ***P < .001, as evaluated by Student's t test
Arginine deprivation is an emerging approach to treat selected tumors. 21 As a targeted anticancer therapy, the efficiency of arginine deprivation is related to ASS1 and OTC expression, two critical enzymes in the urea cycle. 22 We purchased 9 commercially available SCLC cell lines from ATCC without selection of basal expression of ASS1 or OTC. We observed that cell lines with both ASS1 and OTC negative expression were relatively sensitive to BCT-100 treatment, whereas 2 cell lines were relatively resistant to BCT-100 treatment ( Figure 1A,B) . According to the in vitro data, 7 of the 9 cell lines showed response to BCT-100 treatment, which indicated that BCT-100 might be a therapeutic option for most SCLC patients, but not all. Treatment with BCT-100 should be similar to other therapies, for example, chemotherapy and immunotherapy, that not all patients would obtain a positive response. Arginine deiminase depletes arginine to citrulline, which can be converted back to arginine by ASS1 through the urea cycle. Therefore, high expression of ASS1 is the F I G U R E 3 Apoptosis induced by BCT-100 was mitochondrial-dependent and accompanied by reactive oxygen species production. A-C, Elevation of H 2 O 2 (A) and O 2 − (B) as well as decreased glutathione (GSH) level (C) was observed after BCT-100 treatment for 72 hours. D, Downregulation of superoxide dismutase (SOD-1) and thioredoxin reductase 1 (TRXR) was induced after BCT-100 treatment for 72 hours. E, Mitochondrial membrane depolarization was elevated in BCT-100-treated cells. F, Cytochrome C (Cyt C) and Smac were released to cytosol from nucleus following BCT-100 treatment for 72 hours. COX IV and β-actin were used as loading control in mitochondrion (Mito) and cytosol fraction, respectively. Data are shown as mean ± SD of three independent experiments. *P < .05, **P < .01, ***P < .001, as evaluated by Student's t test F I G U R E 4 G 1 cell cycle arrest was induced by BCT-100 in H446, H510A, and H526 cells. Cells were treated with BCT-100 in 15 mU/mL (H446) or 10 mU/mL (H510A and H526) and harvested at different time points. A, Expression of cyclin A2, cyclin B1, cyclin E1, cyclin E2, cyclin-dependent kinase (CDK)2, and CDK4 was suppressed following BCT-100 treatment. B, G 1 cell cycle arrest was observed by cell division distribution using flow cytometry. All data are mean ± SD of three independent experiments. *P < .05, **P < .01, ***P < .001, as evaluated by Student's t test F I G U R E 5 Anticancer effect of BCT-100 in H446 and H510A xenograft models. A,B, Relative tumor size was inhibited (A) and median survival was prolonged (B) in both H446 and H510A xenografts. C, BCT-100 was accumulated in BCT-100 treatment arms (20 mg/kg and 60 mg/kg) in both xenografts. C,D, Serum (D) and intratumoral (E) arginine levels decreased in a dose-dependent manner. All data are shown as mean ± SD of determinations of 5-8 mice in each group. *P < .05, **P < .01, ***P < .001, as evaluated by Student's t test. Con, control predominant resistant mechanism to ADI treatment (ie independent of OTC). Previous studies have reported that silencing ASS1 can enhance sensitivity to ADI treatment in an SCLC cell line. 23, 24 However, arginase depletes arginine to ornithine, which can only be converted back to arginine through both ASS1 and OTC catalytic mechanisms. As such, high expression of ASS1 and/or OTC is the expected resistant mechanism to pegylated arginase treatment. We found that knockdown of OTC in BCT-100-resistant H841 cells increased sensitivity to BCT-100 ( Figure 1C-E) . However, knockdown of OTC in relatively BCT-100-sensitive SW1271 cells had limited effect on further enhancing the sensitivity to BCT-100 ( Figure S1 ).
The expression of OTC could play a more important role in BCT-100 resistant cells than sensitive cells. Nonetheless, knockdown of ASS1 in H69 and H510A cells could not enhance sensitivity to BCT-100 ( Figure S1 ). As none of the SCLC cell lines in this study expressed both ASS1 and OTC, we included the NSCLC A549 cell line with known expression of both ASS1 and OTC (ie intact urea cycle) to serve as a control. In line with our notion, A549 cells were resistant F I G U R E 6 Apoptosis and G 1 cell cycle arrest induced by BCT-100 and localization of BCT-100 in H446 and H510A xenografts. A, Cleaved PARP (C-PARP) was upregulated, whereas cyclin A2, cyclin B1, and cyclin-dependent kinase (CDK)4 were downregulated by BCT-100 in both H446 and H510A xenografts. B, Apoptotic cells were increased in BCT-100 group as revealed by TUNEL assay. C, DAPI, cytokeratin 1, and PEG were used to indicate nucleus, cytoplasm, and BCT-100, respectively. BCT-100 was mainly located in the cytoplasm. Photographs were obtained at 400× magnification to BCT-100 treatment. As expected, BCT-100 was less effective in depleting intracellular arginine level in A549 cells with an intact urea cycle. In contrast, intracellular arginine concentration was significantly depleted in most of the SCLC cell lines treated with BCT-100
( Figure S3 ).
With regard to the mechanisms of drug action, an arginine depletor might play different roles in different cancer cells. Arginine deiminase, the most studied arginine depletor, can induce mitochondrial dysfunction, ROS production, and autophagy in prostate cancer. 25 Arginine deiminase can also inhibit the Warburg effect in leiomyosarcoma and melanoma. 26 Previous studies have shown that rhArg inhibits tumor growth through autophagy, cell cycle arrest and oxidative stress in HCC and breast cancer. 20, 27 The drug resistance mainly involves ASS1 overexpression induced by activation of the Ras/PI3K/ ERK pathway. 28 In our study, we also observed that the expression of ASS1 in the BCT-100 treatment arm was much higher than that of the control, both in vivo and in vitro (data not shown), and could serve as a cellular protective mechanism.
It is well known that the balance of ROS is critical to cell proliferation and survival, and too much or too little ROS may cause cell death. Many chemotherapeutic drugs can induce ROS-dependent apoptosis in cancer cells in vitro and in vivo. [29] [30] [31] Our study implies that ROS was boosted following BCT-100 treatment, and the antioxidant enzyme, GSH, was correspondingly decreased in a dose-dependent manner (Figure 2 ). The essential enzymes in oxidative stress such as SOD-1 and TRXR were downregulated after treatment and are consistent with previous results. 32 Mitochondrion is a unique organelle that plays an essential role in various cellular processes such as energy metabolism, cell differentiation, and apoptosis. As the mitochondria were the main site of ROS production, we tested mitochondrial function and change in mitochondrial-dependent apoptotic biomarker during BCT-100 treatment. JC-1 staining showed that mitochondrial membrane depolarization occurred after BCT-100 exposure. Following mitochondrial stress, both cytochrome C and Smac are released from mitochondria, leading to downstream reactions. Our results showed that these two biomarkers were released from mitochondrion to cytosol ( Figure 3F ). Taken together, excessive production of ROS was responsible for the apoptosis induced by BCT-100 treatment.
The cell cycle is a process in which cells duplicate. This cell division consists of interphase and mitosis and is strictly regulated. The cell cycle checkpoint has become a therapeutic target because it is often dysregulated in cancer cells. 33, 34 Previous studies showed that arginine depletion could inhibit cell proliferation in human HCC and melanoma by cell cycle arrest. 22, 35 It is interesting that the type of cell cycle arrest induced by arginine depletion varies in different cell lines. Arginine deiminase can cause G 1 arrest in neuroblastoma and lymphatic leukemia. 36 Of note, rhArg can induce G 2 /M phase arrest and S phase arrest in Hep3B and HepG2 cells, respectively, even though they originate from HCC. 22 In our project, results affirmed that cell cycle arrest-related biomarkers were decreased in a timedependent manner, and flow cytometry assay showed that G 1 cell cycle arrest was induced after BCT-100 treatment ( Figure 4) . As most downregulated proteins were responsible for G 1 cell cycle arrest and cell cycle distribution was similar, we believe that BCT-100 induced apoptosis through G 1 cell cycle arrest in SCLC.
As arginine depletion therapy may exert systemic effects by altering the tumor microenvironment, it was necessary to determine the anticancer effect of BCT-100 in an animal model. We established xenograft models to prove the anticancer effect of BCT-100 in vivo using H446 and H510A cell lines. Compared with other malignant tumors, 27, 35 the concentrations (20 and 60 mg/kg) we selected were relatively low, because these two cell lines were susceptible to BCT-100 treatment. In addition, the body weight of mice in the BCT-100 treatment arm did not significantly decrease compared with the control group (data not shown), suggesting that the side-effects of BCT-100 might be acceptable. The mechanism in vivo mainly involved apoptosis and G 1 cell cycle arrest and was consistent with in vitro data. Although it is connected with PEG, which facilitates its penetration into cells, BCT-100 is not effective in the nucleus. BCT-100 is a pegylated recombinant human arginase that has high sequence homology (87%) to mouse arginase. The substrate of both human and mouse arginases is identical (arginine). The effectiveness of BCT-100 in causing systemic arginine depletion was shown in our study with markedly reduced systemic and intratumoral arginine levels with BCT-100 treatment.
The formal phase I/II clinical trial of rhArg completed in patients with advanced HCC has been reported. The dosage of rhArg given to patients was 1600 U/kg weekly. The median progression-free survival in the treatment group was significantly improved in patients who received adequate arginine depletion over 2 months compared with those having adequate arginine depletion less than 2 months (6.4 vs 1.7 months, 95% confidence interval, 1.67-1.73; P = 0.01). 37 The latest study also implied that ADI could prolong progression-free survival in patients with ASS1-deficient mesothelioma. 38 The side-effects of arginine deprivation therapy were mainly liver dysfunction, neutropenia, fatigue, and nausea, 18, 38 but it generally did not affect the quality of life of treated patients. Further clinical study of arginine deprivation in cancer patients is still in progress.
Nevertheless, we cannot overlook the limitations in our study.
Although we tested the sensitivity of BCT-100 in 9 SCLC cell lines, the number was still limited. It would be important to expand the number of cell lines in the future to confirm our observed anticancer effects of BCT-100 in SCLC. Because of low toxicity and irritation, PEG has been widely used in the pharmaceutical industry. Many biopharmaceuticals are modified with PEG to enhance bioactivity. Although it would be logical to use PEG as a control in our experiments, we would then lose PEG as a marker to indicate drug distribution and accumulation. In addition, the concentration of PEG used in our study was known to be inert to cells. 39 In conclusion, we revealed that BCT-100 showed an anticancer effect against SCLC through oxidative stress, apoptosis, and cell 
